Interaction Between Nalbuphine and Morphine in PCA

Phase 4

• Conditions: Postoperative Pain

• Registration Number: NCT00155233
• Lead Sponsor: National Taiwan University Hospital

Brief Summary

1. Nalbuphine is opioid mu receptor antagonist and kappa receptor agonist

2. This study was designed to investigate the interaction between nalbuphine and morphine

Detailed Description

1. Nalbuphine is opioid mu receptor antagonist and kappa receptor agonist

2. This study was designed to investigate the interaction between nalbuphine and morphine

3. The analgesic effect and opioid-related side effects will be investigated

Study Timeline

• Study Start: 2005-01
• Status Verified: 2005-06
• Study First Submitted: 2005-09-08
• Study First Submitted QC: 2005-09-08
• Study First Posted: 2005-09-12
• Last Update Submitted: 2005-11-22
• Last Update Posted: 2005-11-23

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 200

Inclusion Criteria

1. Age 18-65 y/o
2. Female patients of ASA physical status I to III
3. Scheduled for elective abdominal hysterectomy, myomectomy, or excision of ovarian tumor

Exclusion Criteria

1. Patients with a definite diagnosis of chronic pain syndrome, psychiatric disorders, or drug abuse (include opioids, NSAIDs, sedatives, antidepressants)
2. Intraoperative fentanyl use > 3 μg/kg
3. Patients with definite diagnosis of esophageal reflux syndrome
4. Use of sedatives, antiemetics, or antipruritics within 24 hours before operation
5. Surgery > 4 hours or laparoscopy surgery

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
analgesic effect

Secondary Outcome Measures

Name	Time	Method
incidence of opioid-related side effects

Trial Locations

Locations (1)

National Taiwan University Hospital; 🇨🇳 Taipei, Taiwan